Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis

British Journal of Cancer

Volumn 72, Issue 6, 1995, Pages 1389-1396

  Pickard, M ^a   Dive, C ^b   Kinsella, A R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 fluorouracil; Apoptosis; Drug resistance; Gi arrest; P53

Indexed keywords

FLUOROURACIL; PROTEIN P53;

APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL CYCLE; CONTROLLED STUDY; DRUG RESISTANCE; EMBRYO; EMBRYO CELL; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; FLUOROURACIL; G1 PHASE; HUMANS; KINETICS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0029589690     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.519     Document Type: Article

References (48)

1. BAAS IO, MULDER JWR, OFFERHAUS JA, VOGELSTEIN B, AND HAMILTON SR. (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172, 13–18.
2. BERLIN RD, AND OLIVER JM. (1972). Membrane transport of purine and pyrimidine bases and nucleosides in animal cells. Int. Rev. Cytol., 42, 287–336.
3. BORRESON AL, HOVIG E, AND SMITH-SORENSEN B. (1991). Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc. Natl Acad. Sci. USA, 88, 8405–8409.
4. CHIOU SK, RAO L, AND WHITE E. (1994). Bcl-2 blocks p53-dependent apoptosis. Mol. Cell. Biol., 14, 2556–2563.
5. CLARKE AR, PURDIE CA, HARRISON DJ, MORRIS RG, BIRD CC, HOOPER ML, AND WYLLIE AH. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362, 849–852.
6. CRIPPS KJ, PURDIE CA, CARDER PJ, WHITE S, KOMINE K, BIRD CC, AND WYLLIE AH. (1994). A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene, 9, 2739–2743.
7. DIVE C, AND HICKMAN JA. (1991). Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64, 192–196.
8. EVAN GI, WYLLIE AH, GILBERT CS, LITTLEWOOD TD, LAND H, BROOKS M, WATERS CM, PENN LZ, AND HANCOCK DC. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69, 119–128.
9. EVANS DL, AND DIVE C. (1993). Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res., 53, 2133–2139.
10. FINLAY CA, HINDS PW, TAN T-H, ELIYAHU D, OREN M, AND LEVINE AJ. (1988). Activating mutations for transformation by p53 produce a gene product that forms an hsp 70-p53 complex with an altered half life. Mol. Cell. Biol., 8, 531–539.
11. FOX M, BOYLE JM, AND KINSELLA AR. (1991). Nucleoside salvage and resistance to antimetabolite anticancer agents. Br. J. Cancer, 64, 428–436.
12. FRITSCHE M, HAESSLER C, AND BRANDNER G. (1993). Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307–318.
13. GANNON JV, GREAVES R, IGGO R, AND LANE DP. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EM BO J., 9, 1595–1602.
14. HALL PA, AND LANE DP. (1994). P53 in tumour pathology: Can we trust immunohistochemistry? Revisited. J. Pathol, 172, 1–4.
15. HOCKENBERRY D, NUNEZ G, MILLIMAN C, SCHREIBER RD, AND KORSMEYER S. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334–336.
16. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, AND HARRIS CC. P53 mutations in human cancers. Science, 253, 49–52.
17. IGGO R, GATTER K, BARTEK J, LANE DP, AND HARRIS A. (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335, 675–679.
18. KASTAN MB, ONYEKWERE O, SIDRANSKY D, VOGELSTEIN B, AND CRAIG RW. (1991). Participation of p53 in the cellular response to DNA damage. Cancer Res., 51, 6304–6311.
19. KINSELLA AR, FISZER-MALISZEWSKA L, MITCHELL ELD, GUO Y, FOX M, AND SCOTT D. (1990). Introduction of the activated N-ras oncogene into human fibroblasts by retroviral vector induces morphological transformation and tumorigenicity. Carcinogenesis, 11, No. 10, 1803–1809.
20. KINSELLA AR, AND HARAN MS. (1991). Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts. Cancer Res., 51, 1855–1859.
21. KUERBITZ SJ, PLUNKETT BS, WALSH WV, AND KASTAN MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491–7495.
22. LANE DP, AND BENCHIMOL S. (1990). P53: Oncogene or antioncogene? Genes Dev., 4, 1–8.
23. LANE DP. (1992). p53, guardian of the genome. Nature, 358, 15–16.
24. LEE JM, AND BERNSTEIN A. (1993). P53 mutation increases resistance to ionising radiation. Proc. Natl Acad. Sci. USA, 90, 5742–5746.
25. LEONARDO AD, LINKE SP, CLARKIN K, AND WAHL GM. (1994). DNA damage triggers a prolonged p53-dependent G, arrest and long-term induction of Cipl in normal human fibroblasts. Genes Dev., 8, 2540–2551.
26. LEVINE AJ, MOMAND J, AND FINLAY CA. (1991). The p53 tumour suppressor gene. Nature, 351, 453–456.
27. LOWE SW, AND RULEY EH. (1993). Stabilization of the p53 tumor suppressor is induced by adenovirus 5 El A and accompanies apoptosis. Genes Dev., 7, 535–545.
28. LOWE SW, SCHMITT EM, SMITH SW, OSBORNE BA, AND JACKS T. (1993a). P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362, 847–849.
29. LOWE SW, RULEY EH, JACKS T, AND HOUSMAN DE. (1993b). P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957–967.
30. MCILWRATH AJ, VASEY PA, ROSS GM, AND BROWN R. (1994). Cell cycle arrests and radiosensitivity of human tumour cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res., 54, 3718–3722.
31. MCMILLAN TJ, AND HART IR. (1987). Can cancer chemotherapy enhance malignant behaviour of tumours? Can Met. Rev., 6, 503–520.
32. NAMBA M, NISHITANI K, FUKUSHIMA F, AND KIMOTO T. (1988). Multi-step carcinogenesis of normal human fibroblasts. Anticancer Res., 8, 947–958.
33. NELSON WG, AND KASTAN MB. (1994). DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14, 1815–1823.
34. PATERSON ARP, LAU EY, DAHLIG E, AND CASS CE. (1980). A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthionosine? Mol. Pharmacol., 18, 40–44.
35. PICKARD M, AND KINSELLA AR. (1995). Reduction in antimetabolite drug resistance by dipyridamole salvage pathway blockade and dependence on cellular response. Biochem. Pharmacol. (submitted).
36. PLAGEMANN PG, AND WOHLHUETER RM. (1980). Permeation of nucleosides, nucleic acid bases and nucleotides in animal cells. Current Topics Membrane Transport, 14, 225–230.
37. RAFF MC. (1992). Social controls on cell survival and cell death. Nature, 356, 397–400.
38. RAO L, DEBBAS M, SABBATINI P, HOCKENBERRY D, KORSMEYER S, AND WHITE E. (1992). The adenovirus El A proteins induce apoptosis which is inhibited by the E1B 19K and Bcl-2 proteins. Proc. Natl Acad. Sci. USA, 89, 7742–7746.
39. SCHIMKE RT, ALT FW, KELLEMS RE, KAUFMAN RJ, AND BERTINO JR. (1977). Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells. Cold Spring Harbor Symp. Quant. Biol, 42, 649.
40. VOGELSTEIN B, AND KINZLER KW. (1992). P53 function and dysfunction. Cell, 70, 523–526.
41. VOJTESEK B, BARTEK J, MIDGLEY CA, AND LANE DP. (1992). An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151, 237–244.
42. WAHL GM, PAGGET RA, AND STARK GR. (1979). Gene amplification causes over production of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J. Biol. Chem., 254, 8679.
43. WEBER G. (1983). Biochemical strategy of cancer cells and the design of chemotherapy. G.H.A. Clowes Memorial Lecture. Cancer Res., 43, 3466.
44. WHITE E, SABBATINI P, DEBBAS M, WOLD WM, KUSHER DI, AND GOODING LR. (1992). The 19-Kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumour necrosis factor β. Mol. Cell. Biol., 12, 2570–2580.
45. WILLIAMS GT. (1991). Programmed cell death: Apoptosis and oncogenesis. Cell., 65, 1097–1098.
46. WU X, BAYLE H, OLSON D, AND LEVINE AJ. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126–1132.
47. YOUNG JD, AND JARVIS SM. (1983). Nucleoside transport in animal cells. Review. Biosci. Res., 3, 309–322.
48. ZHEN Y-S, LUI MS, AND WEBER G. (1983). Effects of acivicin and dipyrimadole on hepatoma 3924A cells. Cancer Res., 43, 1616–1619.